The results (Figure 4) demonstrated that high expression of lncRNA ZEB2-AS1 was associated with a decreased DFS in AML patients (HR = 2.390, 95%CI 1.037–5.507, P = 0.041), with a statistically significant difference. Here, ZEB2 is linked to acute myeloid leukemia.